会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 7. 发明授权
    • HIV replication inhibiting pyrimidines
    • HIV复制抑制嘧啶
    • US08003789B2
    • 2011-08-23
    • US11930835
    • 2007-10-31
    • Bart De CorteMarc René de JongeJan HeeresChih Yung HoPaul Adriaan Jan JanssenFrank Xavier Jozef Herwig Arts, legal representativeRobert W. KavashLucien Maria Henricus KoymansMichael Joseph KuklaDonald William LudoviciKoen Jeanne Alfons Van AkenKoenraad Jozef Lodewijk Marcel Andries
    • Bart De CorteMarc René de JongeJan HeeresChih Yung HoPaul Adriaan Jan JanssenRobert W. KavashLucien Maria Henricus KoymansMichael Joseph KuklaDonald William LudoviciKoen Jeanne Alfons Van AkenKoenraad Jozef Lodewijk Marcel Andries
    • C07D239/48A61K31/505A61K31/506A61P31/18
    • A61K31/505A61K31/5513
    • This invention concerns the use of compounds of formula the N-oxides, pharmaceutically acceptable addition salts, quaternary amines, stereochemically isomeric forms thereof, wherein -a1=a2-a3=a4- forms phenyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl with the attached vinyl group; n is 0 to 5; R1 is hydrogen, aryl, formyl, C1-6alkylcarbonyl, C1-6alkyl, C1-6alkyloxycarbonyl, substituted C1-6alkyl, substituted C1-6alkyloxyC1-6alkylcarbonyl; R2 is hydroxy, halo, optionally substituted C1-6alkyl, C2-6alkenyl or C2-6alkynyl, C3-7cycloalkyl, C1-6alkyloxy, C1-6alkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or di(C1-6alkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, —S(═O)pR6, —NH—S(═O)pR6, —C(═O)R6, —NHC(═O)H, —C(═O)NHNH2, —NHC(═O)R6, —C(═NH)R6, 5-membered heterocyclic ring; L is optionally substituted C1-10alkyl, C2-10alkenyl, C2-10alkynyl or C3-7cycloalkyl; or —X—R3; Q is hydrogen, C1-6alkyl, halo, polyhalo-C1-6alkyl, optionally substituted amino group; Y represents hydroxy, halo, C3-7cycloalkyl, optionally substituted C1-6alkyl, C2-6alkenyl or C2-6alkynyl, C1-6alkyloxy, C1-6alkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono-or di(C1-6alkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, —S(═O)pR6, —NH—S(═O)pR6, —C(═O)R6, —NHC(═O)H, —C(═O)NHNH2, 13 NHC(═O)R6,—C(═NH)R6, aryl; for the treatment of subjects suffering from HIV infection.
    • 本发明涉及式I化合物的N-氧化物,药学上可接受的加成盐,季胺,其立体化学异构体形式的用途,其中-a1 = a2-a3 = a4形成苯基,吡啶基,嘧啶基,哒嗪基,吡嗪基, 乙烯基; n为0〜5; R 1是氢,芳基,甲酰基,C 1-6烷基羰基,C 1-6烷基,C 1-6烷氧基羰基,取代的C 1-6烷基,取代的C 1-6烷氧基C 1-6烷基羰基; R2是羟基,卤素,任选取代的C 1-6烷基,C 2-6烯基或C 2-6炔基,C 3-7环烷基,C 1-6烷氧基,C 1-6烷氧基羰基,羧基,氰基,硝基,氨基,单或二(C 1-6烷基)氨基 ,多卤代甲基,多卤代甲氧基,多卤甲硫基,-S(= O)pR 6,-NH-S(= O)pR 6,-C(= O)R 6,-NHC(= O)H,-C(= O)NHNH 2, NHC(= O)R 6,-C(= NH)R 6,5元杂环; L是任选取代的C 1-10烷基,C 2-10烯基,C 2-10炔基或C 3-7环烷基; 或-X-R 3; Q是氢,C 1-6烷基,卤素,多卤代-C 1-6烷基,任选取代的氨基; Y表示羟基,卤素,C 3-7环烷基,任选取代的C 1-6烷基,C 2-6烯基或C 2-6炔基,C 1-6烷氧基,C 1-6烷氧基羰基,羧基,氰基,硝基,氨基,单 - 或二(C 1-6烷基)氨基 ,多卤甲基,多卤代甲氧基,多卤甲硫基,-S(= O)pR 6,-NH-S(= O)pR 6,-C(= O)R 6,-NHC(= O)H,-C(= O)NHNH 2, NHC(= O)R 6,-C(= NH)R 6,芳基; 用于治疗患有艾滋病毒感染的受试者。
    • 10. 发明申请
    • Hiv Inhibiting 1,2,4-Triazin-6-One Derivatives
    • HIF抑制1,2,4-三嗪-6-酮衍生物
    • US20090012092A1
    • 2009-01-08
    • US11573224
    • 2005-08-10
    • Georges Joseph Cornelius HoornaertAmuri KilondaJan HeeresPaulus Joannes LewiMarc Rene de JongeFrederik Frans Desire DaeyaertHendrik Maarten VinkersLucien Maria Henricus KoymansPaul Adriaan Jan JanssenFrank Xavier Jozef Herwig Arts
    • Georges Joseph Cornelius HoornaertAmuri KilondaJan HeeresPaulus Joannes LewiMarc Rene de JongeFrederik Frans Desire DaeyaertHendrik Maarten VinkersLucien Maria Henricus KoymansPaul Adriaan Jan JanssenFrank Xavier Jozef Herwig Arts
    • A61K31/53C07D253/06A61P31/18
    • C07D253/075
    • The present invention relates to HIV replication inhibitors of formula a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine or a stereochemically isomeric form thereof, wherein ring A and ring B represent phenyl, pyridyl, pyridazinyl, pyrimidinyl or pyrazinyl; n and m are 1 to 4; R1 represents hydrogen; aryl; formyl; C1-6alkylcarbonyl; C1-6alkyloxycarbonyl; optionally substituted C1-6alkyl; C1-6alkyloxyC1-6alkylcarbonyl substituted with C1-6alkyloxycarbonyl; R2 or R4 represents hydrogen; hydroxy; halo; optionally substituted C1-6alkyl; optionally substituted C2-6alkenyl; optionally substituted C2-6alkynyl; C3-7cycloalkyl; C1-6alkyloxy; C1-6alkyloxycarbonyl; C1-6alkylcarbonyloxy; carboxyl; cyano; nitro; amino; mono- or di(C1-6alkyl)amino; polyhaloC1-4alkyl; polyhaloC1-4alkyloxy; polyhaloC1-4alkylthio; —S(═O)pR6; —NH—S(═O)pR6; —C(═O)R6; —NHC(═O)H; —C(═O)NHNH2; NHC(═O)R6; C(═NH)R6; or R7; R2a or R3 represents cyano; aminocarbonyl; amino; halo; NHR13; NR13R14 —C(═O)—NHR13; —C(═O)—NR13 R14; —C(═O)—R15; —CH═N—NH—C(═O)—R16; optionally substituted C1-6alkyl; optionally substituted C1-6alkyloxy; optionally substituted C1-6alkyloxyC1-6alkyl; optionally substituted C2-6alkenyl; optionally substituted C2-6alkynyl; —C(═N—O—R8)—C1-4alkyl; R7 or —X3—R7; X1 or X2 represents —NR1—; —NH—NH—; —N═N—; —O—; —C(═O)—; —C1-4alkanediyl-; —CHOH—; —S—; —S(═O)p—; —X4—C1-4alkanediyl-; —C1-4alkanediyl-X4—; or —C1-4alkanediyl-X4—C1-4alkanediyl-; their use as a medicine, their use for the manufacture of a medicament for the treatment or the prevention of HIV infection; their processes for preparation and pharmaceutical compositions comprising them.
    • 本发明涉及式N-氧化物的HIV复制抑制剂,其药学上可接受的加成盐,季胺或其立体化学异构形式,其中环A和环B表示苯基,吡啶基,哒嗪基,嘧啶基或吡嗪基; n和m为1〜4; R1表示氢; 芳基; 甲酰基 C 1-6烷基羰基; C 1-6烷氧基羰基; 任选取代的C 1-6烷基; 被C 1-6烷氧基羰基取代的C 1-6烷氧基C 1-6烷基羰基; R2或R4代表氢; 羟基; 光环; 任选取代的C 1-6烷基; 任选取代的C 2-6烯基; 任选取代的C 2-6炔基; C 3-7环烷基; C 1-6烷氧基; C 1-6烷氧基羰基; C 1-6烷基羰基氧基; 羧基; 氰基; 硝基 氨基; 单或二(C 1-6烷基)氨基; 多卤代C 1-4烷基; 多卤代1-4烷基氧基; 多卤代 -S(-O)p R 6; -NH-S(-O)p R 6; -C(-O)R 6; -NHC(-O)H; -C(-O)NHNH 2; NHC(-O)R 6; C(-NH)R 6; 或R7; R2a或R3表示氰基; 氨基羰基; 氨基; 光环; NHR13; NR 13 R 14 -C(-O)-NHR 13; -C( - ) - NR 13 R 14; -C(-O)-R 15; -CH-N-NH-C(-O)-R16; 任选取代的C 1-6烷基; 任选取代的C 1-6烷氧基; 任选取代的C 1-6烷氧基C 1-6烷基; 任选取代的C 2-6烯基; 任选取代的C 2-6炔基; -C(-N-O-R 8)-C 1-4烷基; R7或-X3-R7; X1或X2表示-NR1-; -NH-NH-; -N-N- -O-; -C(-O) - ; -C 1-4烷二基 -CHOH-; -S-; -S(-O)p - ; -X4-C1-4烷二基 -C 1-4烷二基-X4-; 或-C1-4烷二基-X4-C1-4烷二基; 它们作为药物的用途,它们用于制备用于治疗或预防HIV感染的药物的用途; 其制备方法和包含它们的药物组合物。